• DexCom released its 2026 “State of Type 2” report ahead of EASD 2026, flagging a gap between CGM benefits and access.
• Survey covered 800+ healthcare professionals, 2,500 Type 2 patients across eight countries; 55% of patients reported limited CGM knowledge.
• Adoption constrained by reimbursement, cited by 90% of U.S. HCPs; 53% in the other surveyed countries.
• Clinical buy-in remains high: 89% of HCPs said CGM helps assess adherence between appointments.
• CGM-GLP-1 pairing rose: 58% of GLP-1 users paired CGM; only 27% of Type 2 non-insulin users did so.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DexCom Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260927863719) on September 28, 2026, and is solely responsible for the information contained therein.